Volume 31, Issue 205 (2-2022)
J Mazandaran Univ Med Sci 2022, 31(205): 115-132 |
Back to browse issues page
Iman Haghani 
, Firoozeh Kermani , Tahereh Shokohi , Mahdi Abastabar , Mahtab Ashrafi Khozani , Mohammad Taghi Hedayati
, Firoozeh Kermani , Tahereh Shokohi , Mahdi Abastabar , Mahtab Ashrafi Khozani , Mohammad Taghi Hedayati
Abstract: (722 Views)
Coronavirus disease 2019 (COVID-19) has seriously spread worldwide. One of the problems of COVID-19 patients is co-infection with other microbial infections such as fungal infections that are severely life-threatening. Mucormycosis, one of these opportunistic fungal diseases that is mistakenly known as black fungal disease, has been reported in Iran and the world. This non-systematic review is intended to review the latest studies in the world and Iran about the incidence of mucormycosis in COVID-19 patients to better understand the disease and its predisposing factors. In general, patients with COVID-19 with underlying diseases, diabetic patients, those treated with immunosuppressive drugs, ICU patients, and patients under invasive mechanical ventilation are at higher risk for mucormycosis. Therefore, early diagnosis, treatment, and prevention methods can be effective in reducing the risk of mucormycosis in COVID-19 patients.
| Rights and permissions | |
 |
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License. |